Atlas Antibodies AB appoints Nille Klæbel as new CEO
Atlas Antibodies is pleased to announce Nille Klæbel as the new CEO with effect from 15 September 2021.
Nille Klæbel joins Atlas Antibodies from her role as CEO Nordics at Philips, a position she has held since 2018. Nille joined Philips back in 2013. Previously she has held senior positions at GlaxoSmithKline, Sanofi and Novo Nordisk.
“We are delighted to welcome Nille as the new CEO of Atlas Antibodies” says Torben Jørgensen, chairman of the Board of Directors and continues: “With her strong background in marketing and sales and knowledge of the life sciences, pharma and healthcare industries, Nille is highly equipped to lead the next important steps in the development of Atlas Antibodies into a global life sciences company.”
“I am thrilled to join Atlas Antibodies. The company is at a truly exciting stage right now, having completed two strategic acquisitions. I look forward to contribute to our continued journey of both organic as well as inorganic growth.”, says Nille Klæbel.
“I also want to thank John Daicic for his commitment, passion and drive during the last four years bringing Atlas Antibodies from being a research company to a much more commercial driven company, including completing two important acquisitions this year. I wish John all the best in his future engagements and career.”, says Torben Jörgensen.
Atlas Antibodies was founded in 2006 as a start-up from the Human Protein Atlas project and has over the last 15 years successfully launched more than 60,000 products for protein research. The company was founded by researchers at the Royal Institute of Technology (KTH) in Stockholm and the Rudbeck Laboratory, Uppsala University in Uppsala to handle the production, marketing and sales of research tools developed by the Swedish-based Human Protein Atlas program. Headquartered in Stockholm, Sweden, Atlas Antibodies provides high-quality reagents for biomedical research, including polyclonal and monoclonal antibodies and QPrESTs. Earlier this year, Atlas Antibodies acquired UK-based HistoCyte Laboratories – a leading supplier of cell line controls for pathology applications, and Swiss-based evitria – an expert provider of antibody expression services.
For more information, please contact:
Torben Jørgensen, chairman of the Board of Directors
firstname.lastname@example.org /+46 707490584